PI3K/ AKT/ HIF-1α経路の異常な活性化により,肝がんにおけるグリコロシスとレンバチニブ耐性が促進される
Jinfeng Wang1, Jianfei Shi1, Lili Mi1
1Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China.
Molecular medicine reports
|August 29, 2025
まとめ
肝がんにおけるレンヴァチニブ耐性は,PI3K/ AKT/ HIF- 1α経路と有酸素糖解の増加と関連している. この経路をLY294002で阻害すると,レンバチニブの感受性が回復し,潜在的な治療戦略が提供されます.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- レンバチニブは進行した肝がん (LC) の第一線治療法ですが,薬剤耐性が有効性を制限しています.
- リンパチドリノシトール3キナーゼ/タンパク質キナーゼB/低酸素誘導因子-1α (PI3K/AKT/HIF-1α) 経路と有酸素糖解は腫瘍の進行と抵抗に関与しています.
- LCにおけるレンバチニブ耐性におけるこの経路と糖解の正確な役割については,さらなる解明が必要である.
研究 の 目的:
- 肝がんにおけるレンバチニブ耐性に対するPI3K/AKT/HIF-1α経路と有酸素糖解の寄与を調査する.
- 抵抗を与える過程におけるこれらの過程のメカニズム的な相互作用を探求する.
- レンバチニブ耐性を克服するためにPI3K/ AKT/ HIF- 1α経路を標的とする可能性を評価する.
主な方法:
- コロニー形成,フローサイトメトリー,トランスウェル解析を用いて増殖,アポトーシス,侵入を評価した.
- グルコースの摂取量,乳酸の産生,細胞内ATP,重要な遺伝子発現を定量化することによって,細胞の有酸素糖解を測定した.
- レンバチニブ耐性 (LR) のLC細胞 (Huh7およびHepG2) に,レンバチニブと併用したPI3K阻害剤LY294002を使用した.
主要な成果:
- レンバチニブ耐性LC細胞は,有酸素糖分解の強化とPI3K/ AKT/ HIF- 1α経路の異常活性化を示した.
- LY294002は,PI3K/ AKT/ HIF- 1α経路とLR細胞における糖分分解活性を抑制した.
- LY294002とレンバチニブを併用した治療は,その経路を抑制し,糖分解を弱め,増殖と侵入を抑制し,アポトーシスを誘発し,LR細胞のG0/ G1細胞サイクル停止を引き起こした.
結論:
- 異なったPI3K/ AKT/ HIF- 1α経路の活性化により,肝がんにおけるレンバチニブ耐性が生じます.
- PI3K/ AKT/ HIF- 1α経路の抑制により,レネバチニブに対する感受性が回復する.
- LY294002とレンバチニブを併用した治療は,肝がん患者のレンバチニブ耐性を克服するための有望な戦略です.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


